Comparison of glucose and insulin response to a test meal and nateglinide, glibenclamide, or placebo in the 15 patients with MODY3 patients
Nateglinide | P1 | Glibenclamide | P2 | Placebo | P3 | |
---|---|---|---|---|---|---|
Plasma glucose (mmol/l) | ||||||
Fasting | 7.9 (5.6) | NS | 7.8 (2.2) | NS | 7.8 (2.7) | NS |
Peak | 9.8 (8.9) | 0.031 | 11.5 (6.6) | 0.031 | 12.7 (7.2) | <0.0001 |
140 min | 9.1 (7.8) | 0.029 | 7.1 (9.2) | 0.0001 | 10.4 (9.9) | 0.0038 |
170 min | 7.3 (7.0) | 0.004 | 6.3 (8.0)* | 0.0005 | 8.3 (10.3) | 0.0018 |
260 min | 6.4 (4.9) | 0.006 | 5.5 (3.9)† | 0.0002 | 7.6 (7.8) | 0.0124 |
ΔPeak‡ | 3.3 (2.9) | 0.031 | 4.5 (3.9) | NS | 4.7 (3.5) | <0.0001 |
Δ140 min‡ | 1.85 (2.85) | 0.026 | −0.3 (5.6) | 0.0019 | 2.7 (4.7) | 0.0008 |
AUC140 min§ | 101 (294) | 0.041 | 186 (391) | 0.027 | 250 (348) | <0.0001 |
Urine glucose (mmol/l) | ||||||
Fasting | 0 (20.4) | NS | 1.4 (37.1) | NS | (21.3) | NS |
140 min | 15.4 (59.8) | NS | 42.7 (74.0) | NS | 33.0 (97.0) | NS (0.06) |
260 min | 3.8 (52.8) | NS | 10.4 (70.1) | NS | 46.0 (67.9) | NS |
Serum insulin (mU/l) | ||||||
Fasting | 5.8 (4.3) | NS | 5.2 (4.5) | NS | 6.0 (5.4) | NS |
Peak | 47.0 (26.0) | 0.023 | 80.4 (71.7) | 0.0002 | 33.7 (24.9) | <0.001 |
AUC140 min§ | 2,912 (1,668) | 0.024 | 3,253 (3,888) | 0.0002 | 1,652 (2,150) | 0.002 |
Hypoglycemia (n)‖ | 0/15 | 0.030 | 6/15 | 0.030 | 0/15 | NS |
Data are median (interquartile range). Each patient participated in the test three times receiving in double-blind random order: 1) placebo at time 0 min and 30 mg nateglinide at 20 min, 2) 1.25 mg glibenclamide at 0 min and placebo at 20 min, or 3) placebo at both 0 and 20 min. The subjects ingested a test meal between 30 and 45 min. P1: nateglinide vs. glibenclamide visits; P2: glibenclamide vs. placebo visits; P3: nateglinide vs. placebo visits.
↵* n = 14 and
↵† n = 12 due to hypoglycemia.
↵‡ Difference between peak or 140 min glucose and fasting glucose.
↵§ AUC, incremental area under the curve during 0–140 min.
↵‖ Plasma glucose ≤3.5 mmol/l.